Study Title

PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation

Study Details

Description:

This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

Sponsor:

Jonsson Comprehensive Cancer Center (UCLA)

Contacts:

Stephanie Lira (Clinical Trials Program Manager)

stephanielira@mednet.ucla.edu

(310) 206-7372

Hamzah Alam (Clinical Research Coordinator)

halam@mednet.ucla.edu

3102067372

Maria Contreras (Clinical Research Coordinator)

mmcontreras@mednet.ucla.edu

3108257336

Drug Details

68Ga-FAPi-46
Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • FAP
Ligand: Small Molecules
Chelator: DOTA
Inclusion
  • Patients who are scheduled to undergo surgical resection or tissue biopsy of the primary tumor and/or metastasis
  • Patient is able to remain still for duration of imaging procedure (up to one hour)
  • Patient can provide written informed consent
  • Patients are ≥ 18 years old at the time of the radiotracer administration.
Exclusion
  • Patient has underlying disease which might interfere with the collection of high quality data
  • Patient is pregnant or nursing
  • Patients with any new cancer therapy between the baseline PET/CT and the investigational FAPI PET/CT

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Not yet provided. Contact Stephanie Lira for more information.

(310) 206-7372

stephanielira@mednet.ucla.edu

XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468